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Background: Human and animal studies support the idea that there are sex differences in the development of
diabetic renal disease. Our lab and others have determined that in addition to Ang II (through the AT1R), growth
hormone (GH) contributes to renal damage in models of renal failure; however, the impact of sex and GH on the
mechanisms initiating diabetic renal disease is not known. This study examined the effect of sex and GH on
parameters of renal damage in early, uncontrolled streptozotocin (STZ)-induced diabetes.
Methods: Adult male and female Sprague–Dawley rats were injected with vehicle (control), STZ, or STZ + GH and
euthanized after 8 weeks.
Results: Mild but significant glomerulosclerosis (GS) and tubulointerstitial fibrosis (TIF) was observed in both kidneys
from male and female diabetic rats, with GH significantly increasing GS and TIF by 30% and 25% in male rats, but
not in female rats. STZ increased TGF-β expression in both kidneys from male and female rats; however, while GH
had no further effect on TGF-β protein in diabetic females, GH increased TGF-β protein in the male rat’s kidneys by
an additional 30%. This sex-specific increase in renal injury following GH treatment was marked by increased MCP-1
and CD-68+ cell density. STZ also reduced renal MMP-2 and MMP-9 protein expression in both kidneys from male
and female rats, but additional decreases were only observed in GH-treated diabetic male rats. The sex differences
were independent of AT1R activity.
Conclusions: These studies indicate that GH affects renal injury in diabetes in a sex-specific manner and is
associated with an increase in pro-inflammatory mediators.
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Growth hormone (GH) has been shown to exacerbate
progression of kidney damage in a number of experimen-
tal models of renal disease [1-4], including diabetes [5]. In-
deed, the kidney appears to be very sensitive to GH, as
seen in male transgenic mice overexpressing GH that
present with glomerular hypertrophy, increased glomeru-
lar cell turnover, and increased extracellular matrix accu-
mulation leading to diffuse glomerulosclerosis [6,7]. It has
also been reported that diabetic patients present with
dysregulation of GH, which ultimately results in overall
GH hypersecretion [8]. Diabetic mice treated with a* Correspondence: mulrones@georgetown.edu
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reproduction in any medium, provided the orspecific GH receptor antagonist showed none of the
diabetes-associated renal hypertrophy or glomerular en-
largement and had lower urinary albumin excretion than
untreated diabetic mice [5,9]. These results were con-
firmed in GH receptor antagonist transgenic mice that
were protected against diabetes-induced renal changes
[10]. Collectively, these findings strongly suggest that GH
plays a role in the development of diabetic renal disease;
however, the mechanism whereby GH acts on the kidney
is not completely understood. While GH is known to
stimulate liver and tissue insulin-like growth factor (IGF-
1), this IGF-I associated mechanism does not appear to
play a role in diabetic renal damage [8].
In the streptozotocin (STZ)-induced diabetic rat, a
common diabetic rat model, normal GH secretion is
dysregulated [11]. Indeed, by 6 h post-STZ, pulsatile GH
secretion is dramatically reduced in male rats and isl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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STZ is also observed in female rats (unpublished data
from this laboratory). This decrease seen in GH levels is
opposite of what is seen in patients with type 1 diabetes,
where GH levels are dysregulated, and usually elevated
compared to nondiabetic control patients [8,12]. We
hypothesize that the loss of GH in the STZ model im-
pacts the development of diabetic kidney disease and
that using an STZ model with GH supplementation will
more accurately reflect the human condition.
Another important aspect of human diabetes is the in-
creasing evidence of sex differences in the development
and/or severity of diabetic renal disease [13-16], and al-
though sex hormones appear to be key factors [17,18],
the exact reasons for the differences are still not clear. In
addition, both sex and diabetes are key factors contribut-
ing to cardiovascular diseases [19-22]. Our lab has previ-
ously reported the link between GH and the development
of renal disease following unilateral nephrectomy [4,17].
More importantly, we have identified sex differences in
the effects of GH on remnant kidney growth and path-
ology and determined that GH is crucial in compensatory
renal growth in male animals, but not in female animals
[17,23]. While many renal diseases have been shown to
progress at different rates between the sexes, these find-
ings indicate that there are differential pathologic path-
ways governed by gonadal steroids, with testosterone
promoting a GH-dependent, hypertrophic renal growth,
and 17β-estradiol promoting IGF-1-associated hyperplas-
tic renal growth [16,17,23]. On this basis, we hypothesize
that there also may be sex differences in GH-mediated
diabetic renal damage.
Taken together, there is a strong rationale for sex differ-
ences in the development of diabetic renal disease, and
GH may be a contributing factor to these differences.
Since sex hormones can affect renal hemodynamics,
mesangial cell proliferation, extracellular matrix metabol-
ism, as well as synthesis and release of vasoactive agents
[15], their role in diabetes could help define sex-specific
therapeutic interventions. Thus, the objective of this study
was to determine the effects of sex and GH on mediators
of renal damage and subsequent renal disease in the initial
stage of uncontrolled diabetes.
Methods
Animals
Male and female Sprague–Dawley rats (Harlan, Madison,
WI, USA) (12–14 weeks of age), were randomly divided
into three treatment groups for each sex: control (n = 10),
streptozotocin (n = 8), and STZ +GH (n = 9). After fasting
animals overnight, diabetes was induced by an intraperito-
neal injection of STZ (55 mg/kg in 100 μl 0.1 M citrate) in
the STZ and STZ +GH groups, whereas control animals
were injected with vehicle (100 μl 0.1 M citrate). Becausethere are sex differences in GH secretory patterns (regular
high pulses in males [24]) and higher baseline, erratic, and
low pulses in females [23], we performed a pilot study
using twice daily GH injections (which we have used suc-
cessfully in many studies) vs continual GH release via an
osmotic minipump, and the damage to both male and fe-
male kidneys were similar between each method (data not
shown). We decided to use the GH injections primarily be-
cause of our past success with this method. The GH-
supplemented diabetic rats (STZ + GH) were injected
subcutaneously with GH twice daily over the 8-week
duration of the experiment (2.5 μg in 100 μl saline between
9–11 a.m. and 3–5 p.m.), whereas the non-GH-treated rats
were injected twice daily with vehicle (100 μl saline).
This dose has been shown to increase plasma GH to
80–100 mmol/l within 30 min, which is similar to
levels observed in male rats [17]. All animals were fed
a phytoestrogen-free diet (Harlan) and given tap water
ad libitum. Twenty-four-hour urine was collected from
rats placed in metabolic cages after 0, 4, and 8 wks of
treatment. Diabetic animals were not treated with in-
sulin in order to mimic the changes present in early
uncontrolled diabetes. Plasma glucose was determined
using a One-Touch Ultra glucometer (LifeScan, Milpitas,
CA, USA) from blood collected via tail puncture at day 0
and thereafter on a weekly basis during the course of the
entire experiment. Animals were sacrificed by decapita-
tion. The left kidney was weighed, removed, and snap-
frozen in liquid nitrogen for analysis of TGF-β, MMP-2,
MMP-9 protein expression by Western blotting and AT1R
activity by radioligand binding. The right kidney was
fixed in 4% paraformaldehyde for assessment of
glomerulosclerosis and tubulointerstitial fibrosis as
well as tissue expression of monocyte chemoattractant
protein-1 (MCP-1)- and CD68-positive cells by immuno-
histochemistry. Urine albumin concentration was deter-
mined by ELISA (Exocell, Philadelphia, PA, USA) and
multiplied by urine volume to calculate urine albumin ex-
cretion. All procedures were approved by the Georgetown
University Animal Care and Use Committee.
Western blotting
Renal cortex was prepared for Western blotting by rap-
idly dissecting frozen kidney tissue on ice, followed by
homogenization using the Bio-Rad’s Criterion system
(Hercules, CA, USA), as previously described [25].
Briefly, total protein (30 mg) was loaded in each lane
followed by electrophoresis on 10% polyacrylamide gels.
The gels were incubated with one of the following primary
antibodies: TGF-β (1:1,000, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), MMP-2 (1:500, Oncogene Science,
Cambridge, MA, USA), and MMP-9 (1:500, Oncogene
Sciences). Specific bands were detected by chemilumines-
cent peroxidase (Amersham, Buckinghamshire, UK) and
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termined by normalizing each band to lane total protein
density determined by a Coomassie blue stain. Corre-
sponding samples of male and female homogenates were
compared side by side on the same gel.AT1R binding
Because we have previously reported sex-dependent in-
creases in AT1R binding by GH in another model of
renal disease [17] and identified sex-hormone-dependent
effects on AT1R binding [25], we examined whether
renal AT1R binding was altered by GH in diabetic male
and female animals. Specific AT1R binding was deter-
mined in isolated glomeruli (5 μg/tube) using 125I-[Sar1,
Ile8]Ang II as the radioligand, as previously described
[22]. Specific binding was defined as the total binding in
the presence of radioligand minus the amount of bind-
ing in the presence of radioligand and 500 μM cold
[Sar1, Ala8]Ang II.Glomerulosclerotic index
Periodic acid Schiff-stained, paraffin-embedded kidney
sections (3 μm) were examined using a Nikon Eclipse
E600 (Tokyo, Japan) light microscope to assess the
glomerulosclerotic index (GSI), as previously described [20].Tubulointerstitial fibrosis index
Masson’s trichrome-stained 3-μm paraffin-embedded
kidney sections were examined using a Nikon Eclipse
E600 light microscope to assess the TIFI, as previously
described [26].Immunohistochemistry
Paraffin sections at 3 μm were incubated in 10% normal
goat serum for 30 min at room temperature, followed by
incubation overnight at 4°C with one of the following
primary antibodies: MCP-1 (1:100, Santa Cruz), CD68
(1:100, Oncogene Sciences), and TGF-β (1:400, Santa
Cruz). Negative controls were incubated in 10% normal
goat serum only. Positive immunoreactivity was detected
using the Envision Plus peroxidase method (Dako,
Carpentaria, CA, USA), followed by counterstaining the
slides with Mayer’s hematoxylin. The images were taken
at × 400. The samples were quantitated by analyzing 25
randomly chosen visual fields per animal. The positive
cell number was determined by counting the number of
cortical positive cells (brown staining) in 25 different
fields per animal from each group and expressed as the
average percentage of brown staining in the field of
view. Images were quantified using Image145 J soft-
ware (National Institutes of Health http://rsbweb.nih.gov/ij/).Statistics
Statistical analysis between groups was performed using
one-way ANOVA, with Student-Neuman-Keul’s post hoc
tests. Significance was designated at P < 0.05.
Results and discussion
Effects of GH and sex on blood glucose and albuminuria
Blood glucose levels were elevated more than fourfold in
all diabetic animals starting by week 1 (control, 100 ±
11 mg/dl; STZ, >400 mg/dl; STZ +GH, >400 mg/dl; P <
0.01, control vs STZ or STZ +GH) and remained ele-
vated throughout the experimental period (data not
shown). There was no additional effect of GH on blood
glucose nor were there sex differences seen in blood glu-
cose within treatment groups, with the limitation that all
STZ groups were shown with blood glucose above
400 mg/dl.
Although the male rats were heavier than the females
at the outset of the experiment, control rats of both
sexes gained >15% body weight (BW) over the 8-week
experiment (Table 1). STZ treatment caused the male
rats to lose 29% of their BW over the experimental
period. GH treatment had no additional effect on BW in
the male rats. The females also lost BW after STZ treat-
ment; however, the amount of BW loss (11%) was much
less compared to the males.
Kidney weight (KW) was not affected by STZ treat-
ment or GH supplementation in the male rats (Table 1).
In contrast, KW increased by 1.4-fold in the females
after STZ treatment, while GH supplementation had no
additional effect.
STZ treatment reduced heart weight (HW) in the male
rats and GH supplementation had no additional effect
(Table 1). In comparison, STZ had no effect on HW in
the females either in the presence or absence of GH
supplementation.
Urine albumin excretion was elevated in both male
(3.5-fold) and female (3.9-fold) STZ-treated rats com-
pared with their same-sex controls (Table 1). GH supple-
mentation increased the amount of albumin excreted in
the diabetic male to 5.2-fold but had no additional effect
on albuminuria in the diabetic female.
Effects of GH and sex on glomerular and tubular damage
STZ treatment was associated with modest glomerular in-
jury in both sexes as evidenced by a fourfold increase in
the GSI in both male and female diabetic rats (Figure 1A).
GH supplementation magnified the effect of STZ on GSI
by 30% in the male rats but had no additional effect in the
females. Examination of the renal pathology indicates that
the diabetes-induced renal damage was associated with
modest mesangial expansion in both sexes (Figure 1B).
These indicators of damage were more prevalent in the
STZ +GH males.
Figure 1 Effect of sex on GSI in Control and diabetic rats treated with and without GH. (A) STZ treatment significantly increased the GSI in
both sexes, while GH treatment significantly increased GSI beyond STZ alone in males only. *P < 0.01 vs. control of the respective sex, #P < 0.05 vs
male STZ. (B) Representative pictures of periodic acid Schiff-stained sections. Diabetic kidneys were characterized by moderate glomerulosclerosis,
as evidenced by mesangial expansion (arrowheads), and is seen more abundantly in male STZ + GH than STZ alone. Original magnification is ×
400, and bar represents 100 μm.
Table 1 Effect of treatment on body weight, kidney weight, heart weight, and albuminuria of rats
Initial BW (g) Final BW (g) KW (g) HW (g) Albuminuria (mg/day)
Female
Control 244.5 ± 5.5 284.0 ± 9.0 1.52 ± 0.04 0.99 ± 0.11 2.9 ± 1.2
STZ 225.3 ± 1.8 201.0 ± 4.4* 2.20 ± 0.02* 0.94 ± 0.04 11.3 ± 2.7*
STZ + GH 227.4 ± 2.3 227.4 ± 18.7 2.36 ± 0.11* 0.95 ± 0.07 8.6 ± 1.8*
Male
Control 369.7 ± 2.7 461.0 ± 14.0 2.68 ± 0.10 1.42 ± 0.02 3.1 ± 0.4
STZ 352.8 ± 8.1 251.8 ± 22.0** 2.75 ± 0.21 1.00 ± 0.08** 10.4 ± 0.8**
STZ + GH 353.0 ± 8.7 249.0 ± 25.6** 2.85 ± 0.19 1.13 ± 0.10** 16.1 ± 1.7**,***
BW, Body weight; KW, Kidney weight; HW, Heart weight. *P > 0.05 vs sham female; **P > 0.05 vs sham male; ***P > 0.05 vs STZ male by one-way ANOVA and Tukey’s
post hoc tests. (n = 8 for each group).
Whitney et al. Biology of Sex Differences 2013, 4:12 Page 4 of 11
http://www.bsd-journal.com/content/4/1/12
Whitney et al. Biology of Sex Differences 2013, 4:12 Page 5 of 11
http://www.bsd-journal.com/content/4/1/12TIFI also increased after STZ (2.5-fold) treatment in
both male and female rats. While GH supplementation
further increased the TIFI in both sexes, the magnitude
of this GH effect was greater in the male (20%) than in
the female (5%) rats (Figure 2A). The tubular dilation
and fibrosis observed in Masson’s trichrome-stained sec-
tions was magnified by the presence of GH in the dia-
betic animals (Figure 2B).
Effect of sex and GH on renal markers of inflammation
(MCP-1 and CD68)
MCP-1 is stimulated in response to pro-inflammatory
cytokines (such as TGF-β) and stimulates immune cell
infiltration of the tissue [24]. STZ treatment increased
MCP-1-positive cells threefold in both male and female
rats (Figure 3). While GH had no additional effect inFigure 2 Effect of sex on TIFI in control and diabetic rats treated with
both sexes, and while GH treatment increased the TIFI in both sexes, the in
respective sex, #P < 0.05 vs STZ of the respective sex, $P < 0.05 vs female GH
Diabetic kidneys were characterized by moderate tubule interstitial fibrosis,
staining) and tubular dilation, and these changes (blue staining and larger t
most abundantly in STZ + GH-treated males. Original magnification is × 400female rats, there were 3.5 times more MCP-1+ cells in
kidneys from STZ +GH male rats when compared to
STZ alone (Figure 3A). Representative staining is shown
in Figure 3B.
Representative staining of CD68+ cells, which indi-
cates macrophage activation and tissue inflammation, is
illustrated in Figure 4B. There was no evidence of CD68
staining in control animals of either sex. There were no
significant changes in CD68 staining seen in kidneys
from either male or female STZ-only-treated animals.
However, in the presence of GH there was a significant
fourfold increase in CD68+ cells (brown staining) in both
the glomeruli and in surrounding tubulointerstitium in
male kidneys, but not in female kidneys (Figure 4A,B). This
finding further supports the concept that the male kidney
is a target for GH-related damage and inflammation.and without GH. (A) STZ treatment significantly increases the TIFI in
crease is greater in males than in females. *P < 0.01 vs. control of the
. (B) Representative pictures of Masson’s trichrome-stained sections.
evidenced by the presence of extracellular matrix deposits (blue
ubules) are seen more abundantly in STZ + GH-treated animals, and
, and bar represents 100 μm.
Figure 3 Effects of STZ and GH treatment on renal MCP immunoreactivity. (A) STZ increases the MCP-1 staining in kidneys from diabetic
male and female rats; however, GH treatment increased MCP-1 only in kidneys from diabetic male rats. *P < 0.01 vs control and #P < 0.05 vs
female. (B) Representative images show an increase in brown staining on dilated and injured tubules (solid arrows show dilated tubules, and
dashed arrows show brown staining). Original magnification is × 400, and bar represents 100 μm.
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MMP-9
The effect of GH on renal TGF-β protein expression in
diabetic kidneys is illustrated in Figure 5. STZ treatment
increased TGF-β protein expression equally in both the
male (Figure 5A) and female kidney cortexes (Figure 5B)
(approximately fivefold greater than control, P < 0.05).
However, while GH had no additional effect on TGF-β
protein in diabetic female kidneys, there was a dramatic,
GH-dependent, tenfold increase in TGF-β protein in
male kidneys (P < 0.01).
There was a significant 20% decrease in both MMP-2
and MMP-9 protein expression in kidneys from male
STZ-diabetic rats compared to values in nondiabetic
controls. Interestingly, MMP-2 and MMP-9 protein ex-
pression was reduced by 40% in female STZ-treatedanimals compared to controls (Figure 6A–D). However,
while GH further decreased MMP-2 and MMP-9 in the
male kidneys, there was no further effect of GH in fe-
male STZ-treated kidneys (Figure 6B,D).
Effect of GH on glomerular AT1R binding
Renal glomerular AT1R binding was tested. As previously
reported [25], AT1R binding was significantly lower in the
glomeruli from nondiabetic female animals compared with
male animals (4,234 ± 178 cpm vs. 6,742 ± 210 cpm, P <
0.05). AT1R binding was not significantly changed in STZ-
only-treated male and female glomeruli (3,934 ± 1,084 cpm
vs. 5,037 ± 596 cpm). However, in both male and female
STZ+GH-treated rats, AT1R binding significantly increased
as compared to control and STZ-only-treated rats (8,462 ±
923 cpm vs. 9,562 ± 1,472 cpm, P < 0.05) (graph not shown).
Figure 4 Effects of STZ and GH treatment on renal CD68 immunoreactivity. (A) No significant changes were observed in CD68 protein
expression in kidneys from diabetic female rats. While CD68 staining was not increased in kidneys from STZ-only-treated rats, GH significantly
increased CD68 staining in the glomeruli and tubules in diabetic male, but not female, rats. *P < 0.01 compared to all other data (B)
Representative images of CD68+ cells in kidney sections (dark brown dots). The intensity of staining is significantly increased in the
STZ + GH-treated males. Original magnification is × 400, and bar represents 100 μm.
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While previous studies have highlighted the issues of sex
differences and GH effects in diabetic renal disease
separately, the present work shows sex-related differ-
ences in response to GH in diabetic renal disease. The
presence of GH appears to be necessary for the develop-
ment of significant renal damage, but there are sex dif-
ferences in the pattern of effects of GH on the diabetic
kidney. Our findings have determined that GH has a
greater overall effect in the male animals in proteins as-
sociated with renal damage (increased TGF-β, MCP-1
and CD-68, and lowered MMPs) and markers of path-
ology (increased GSI, TIFI, and albuminuria). GH was
given at a fixed amount that has been shown to achieve
levels similar to that observed in adult male rats(unpublished data). Because it was not adjusted for BW,
the female rats received a greater proportional dosage,
yet it did not exacerbate the renal damage, providing
further evidence that the effect on the kidneys is specific
to male animals. These findings extend previous reports
and provide intriguing areas for future study. Further-
more, the fact that human diabetes is associated with
overall elevated plasma GH [8,12] increases the rele-
vance of the present work.
The STZ-treated rat is an excellent model for studying
the role of GH in diabetes, since STZ treatment results
in the suppression of pulsatile GH release and low
plasma GH levels [11]: this low GH model can then be
compared to STZ + GH replacement to identify GH-
related changes in diabetes. This has allowed us to
Figure 5 Effect of sex on renal cortical TGF-β protein abundance in control and diabetic rats treated with and without GH. (A) STZ and
STZ + GH treatment increased female cortical TGF-β protein levels from control equally. *P < 0.01 vs. female controls. (B) STZ treatment increased
male TGF-B levels significantly, and STZ + GH significantly increased those levels. *P < 0.01 vs. male controls, #P < 0.05 vs. male STZ.
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male and female diabetic animals. Consistent with previ-
ous reports, in both male and female animals, STZ treat-
ment increases cortical TGF-β expression and decreases
cortical MMP-2 and MMP-9 [27,28]. While GH in-
creases AT1R binding in the diabetic female kidney, it
does not increase other proteins associated with renal
inflammation and damage (e.g., TGF-β, MCP-1, CD68,
and MMPs) or exacerbate renal pathology. Our findings
indicate that there are both AT1R-dependent and AT1R-
independent actions of GH in the female diabetic kidney.
Males showed a similar response to STZ, but all of the
protein changes were amplified with GH and directly as-
sociated with exacerbation of renal morphologic damage.
This differential GH action may be mediated by interac-
tions involving testosterone and GH. Testosterone treat-
ment alone has been shown to increase renal TGF-β
mRNA and protein levels in vivo, which was followed by
an increase in glomerulosclerosis as well as an increase
in lymphocyte and macrophage infiltration [29]. These
protein changes and resulting pathology were reversedwith flutamide treatment (a nonsteroidal antiandrogen).
In the present study, we did not see sex differences with
STZ treatment alone, suggesting that both testosterone
and GH are needed to uncover these sex differences.
Evidence suggests that a pro-inflammatory response
contributes to the development of diabetic renal disease
[30-32]. The infiltration of immune cells seen in many
glomerular diseases could cause structural damage
through the release of proteolytic enzymes and oxygen-
free radicals, glomerular remodeling by the release of
growth factors, or glomerular functional alternations
through the release of pro-inflammatory cytokines [33,34].
Previous studies have shown that elevations in cytokines,
such as TGF-β and IL-6, presage the development of the
disease [30,35,36]. This pattern has also been found in the
current study, and importantly, we found sex differences
associated with this pro-inflammatory response. In strong
support of differential GH-related mechanisms is the find-
ing that GH has a dramatic effect on renal TGF-β in dia-
betic male animals, but not in female animals. This
increase is directly correlated with exacerbated renal
Figure 6 Effect of sex on renal cortical MMP-2 and MMP-9 protein abundance in control and diabetic rats treated with and without
GH. (A) STZ and STZ + GH treatments significantly decrease MMP-2 levels in female mice compared to control. *P < 0.01 vs. female controls. (B)
STZ significantly decreases MMP-2 protein levels in male mice compared to control, and STZ + GH treatment is significantly lower than STZ alone.
*P < 0.01 vs. male control, #P < 0.05 vs. male STZ. (C) STZ and STZ + GH treatments significantly decrease female MMP-9 levels than in controls.
*P < 0.01 vs. female controls. (D) STZ significantly decreases MMP-9 protein levels in male mice compared to control, and STZ + GH treatment is
significantly lower than STZ alone. *P < 0.01 vs. male control, #P < 0.05 vs. male STZ.
Whitney et al. Biology of Sex Differences 2013, 4:12 Page 9 of 11
http://www.bsd-journal.com/content/4/1/12damage (increased GSI, TIFI, and albuminuria) in the
male kidney. A previous study in STZ-diabetic mice
reported that MCP-1 promotes renal damage [31]. In our
study, elevations in MCP-1 were also associated with renal
damage, but importantly, the stimulation of MCP-1 by
GH is also affected by the sex of the animal. Interestingly,
while MCP-1 is elevated to the same extent in the
STZ-only-treated male and female rats, CD68+ cells
(representing activated macrophages) are only elevated
in the STZ + GH-treated male rat kidneys. This sug-
gests that the 2-month period of untreated diabetes is
sufficient to produce renal damage but that the exacerba-
tion of the damage in the male may be due to the activa-
tion of the macrophages, whereas the pro-inflammatory
damage observed in the STZ-only-treated animals may be
independent of this effect.
The stimulation of TGF-β by GH has been reported
by others [5]; however, sex differences are a novel find-
ing and suggest that another mechanism is modulating
the effect of GH on TGF-β in the female. Potentially,GH might use testosterone as a mediator for an increase
in TGF-β; this might provide a layer of protection in the
female against some of the early damage observed in the
diabetic male. Indeed, a relationship has been suggested
between E2 and TGF-β since E2 supplementation in
(nondiabetic) TGF-β transgenic mice significantly re-
duces GS and TIF [37]. In our diabetic females, the pres-
ence of E2, albeit at a reduced level [26], may provide
this protection against the actions of GH on TGF-β. Fu-
ture studies in ovariectomized diabetic females with or
without GH could illuminate this issue.
The concept that GH may provide another target for
therapy in diabetes has been suggested [10] and is sup-
ported by many animal studies over the past 15 years
[9,10,37]. Our data support the idea of this GH pharmaco-
logic therapy for the treatment of diabetic kidney disease
but suggest that it is especially relevant in males. Previous
reports of GH antagonist treatment from the onset of dia-
betes found a normalization of diabetes-induced renal ef-
fects, including reduced renal hypertrophy, glomerular
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studies were only in male experimental animals [38]. It
has also been shown that late intervention with a GH an-
tagonist resulted in regression of some of diabetes-
associated renal changes [9]. The present findings suggest
that this potential therapy may be useful only in men.
In conclusion, sex differences exist in the mechanisms
governing early, uncontrolled diabetes in the presence of
GH. The male response to GH indicates significantly more
pathology and damage than in females, suggesting evidence
for differential sex-related pharmacologic treatments.
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